<DOC>
	<DOCNO>NCT01567904</DOCNO>
	<brief_summary>Primary Objective : - To assess pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter Semuloparin [ AVE5026 ] ( assessed anti-Xa activity Semuloparin ) child order determine dose assess clinical efficacy/safety study population . Secondary Objective : - To assess tolerability Semuloparin administer weight-adjusted , daily dose 30 day patient le 18 year age central venous line .</brief_summary>
	<brief_title>Study AVE5026 Weight-adjusted Doses Children With Central Venous Line</brief_title>
	<detailed_description>The maximum study duration participant 68 day break follow : - Screening period : 6 day , - Treatment period : minimum 6 day maximum 30 day , - Follow-up period end study visit perform 4 week ( 30 +/-2 day ) post treatment . Enrollment stagger age group start old child ( ≥12 year ) . In young age group , enrolment plan initiate follow review Data Monitoring Committee ( DMC ) clinical safety data available PK PD data first 3 7 child previous old age group . Enrollment infant &lt; 3 month plan initiate recruitment patient ≥3 month complete data analyze DMC .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>Inclusion criterion : age ≥38 gestational week &lt; 18 year ; Central Venous Line implant expected duration ≥6 day study enrolment ; Patient hospitalize able receive daily injection least 6 day provide plasma sample Day 4 , 5 6 prespecified time point ; Written inform consent sign legal representative ( ) accordance local regulation , possibly assent form child ( country/age specific ) . Exclusion criterion : Patient anticoagulant therapy contraindicate ; Planned treatment antithrombotic agent within 2 week prior enrolment course study ; Any previous exposure Semuloparin ( e.g . previous enrolment current study ) ; Documented history heparininduced thrombocytopenia ; Severe thrombocytopenia ( platelet &lt; 50 x 109/L ) ; Active bleeding ; Recent ( less 3 week prior enrollment ) brain , spinal ophthalmologic surgery ; Uncontrolled hypertension characterize sustain systolic pressure diastolic pressure great 2 standard deviation agerelated norm ; Severe hepatic disease ( e.i . 2.5 time upper limit age hepatic enzyme ) ; Severe renal insufficiency ( estimate creatinine clearance &lt; 30 ml/min use Schwartz formula ) ; Any condition , opinion Investigator , would expose patient unfavorable risk/benefit ratio ; Presence history drug hypersensitivity ; Any patient currently involve another clinical trial investigational drug accord applicable regulation ; Any patient parent ( ) /legal guardian ( ) , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development ; Any patient parent ( ) /legal guardian ( ) could contact case emergency ; Pregnant breastfeed female ; Female childbearing potential unwilling abstain sexual intercourse therefore risk become pregnant protect highly effective contraceptive method birth control and/or unwilling unable test pregnancy . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>thrombosis</keyword>
	<keyword>Central Venous Line</keyword>
	<keyword>CVL</keyword>
</DOC>